Latest from Johns Hopkins Cancer Center

Mismatch repair-deficient gastrointestinal tumors are highly responsive to checkpoint blockade with anti-PD-1 therapy.
Emmanuel Antonarakis, MBBCh, associate professor of Oncology, associate professor of Urology at Johns Hopkins Medicine, discusses the use of galeterone in prostate cancer.
With the rapid pace of change in precision medicine, insurance companies and federal policymakers are going to have to adjust for far more variance in the ways patients are treated, even though insurance plans and federal policy by nature require a measure of standardization.
There are reasons to suggest that immune checkpoint inhibitors may be successful against central nervous system tumors, including glioblastoma.
David S. Ettinger, MD, discusses recent advancements in NSCLC, specifically with immunotherapy, and explains challenges that have stemmed from these developments.
Tasquinimod, a drug that showed great promise in phase II trials, failed to improve overall survival in a phase III trial in men with treatment-naïve metastatic castration-resistant prostate cancer.
Ten-story building named for Albert P. "Skip" Viragh Jr. planned for the northeast corner of Fayette Street and North Broadway.
Patients who have HPV 16 DNA in their saliva following treatment of their oropharyngeal cancer are more likely to have their cancer recur, and a prospective cohort study has shown that a simple mouth rinse can be used to detect it.
Publication Bottom Border
Border Publication